Highlights of This Issue  4491

SPECIAL FEATURES

Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis
Michael L. Maitland
See article p. 4647

X-linked Inhibitor of Apoptosis: A Chemoresistance Factor or a Hollow Promise
Hamid Kashkar

Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy
Alessia Montagnoli, Jürgen Moll, and Francesco Colotta

DNA Repair: A Reinvigorated Therapeutic Target
Susan E. Bates

DNA Damage and Repair in Translational Oncology: An Overview
Eddie Reed

Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
Christina M. Annunziata and Joyce O'Shaughnessy

Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
Ruth Plummer

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
Christophe E. Redon, Asako J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner, Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, and Yves Pommier

Molecular Pathways

Epigenetic Modifications in Double-Strand Break DNA Damage Signaling and Repair
Dorine Rossetto, Andrew W. Truman, Stephen J. Kron, and Jacques Côté

“Contextual” Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair
Norman Chan and Robert G. Bristow

HUMAN CANCER BIOLOGY

Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer

System-Level Analysis of Neuroblastoma Tumor–Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma
Olena Morozova, Milijana Vojvodic, Natalie Grinshtein, Loen M. Hansford, Kim M. Blakely, Alexandra Maslova, Martin Hirst, Timothee Cezard, Ryan D. Morin, Richard Moore, Kristen M. Smith, Freda Miller, Paul Taylor, Nina Thiesen, Richard Varhol, Yongqian Zhao, Steven Jones, Jason Moffat, Thomas Kislinger, Michael F. Moran, David R. Kaplan, and Marco A. Marra

CANCER THERAPY: PRECLINICAL

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi, Karrune Woan, Danielle L. Gilvary, Eva Sahakian, Sheng Wei, and Julie Y. Djeu

Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice
Kameswaran Ravichandran, Balaiya Velmuruigan, Mallikarjuna Gu, Rana P. Singh, and Rajesh Agarwal
CANCER THERAPY: CLINICAL

4654 Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor 1 Receptor Inhibition

4666 An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

4675 Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists
Stephen V. Liu, Andrew V. Schally, Debra Hawes, Shigang Xiong, Laden Fazli, Martin Gleave, Jie Cai, Susan Groshen, Frank Brands, Juergen Engel, and Jacek Pinski

IMAGING, DIAGNOSIS, PROGNOSIS

4607 Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers
Maha Ayyoub, Pascale Pignon, Danijel Dojcinovic, Isabelle Raimbaud, Lloyd J. Old, Immanuel Luescher, and Danila Valmori

4616 Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

4625 Correlated Expression of CD47 and SIRPA in Bone Marrow and in Peripheral Blood Predicts Recurrence in Breast Cancer Patients
Makoto Nagahara, Koshi Mimori, Akemi Kataoka, Hideki Ishii, Fumiki Tanaka, Tsuyoshi Nakagawa, Takanobu Sato, Shinji Ono, Kenichi Sugihara, and Masaki Mori

4636 Jumonji Domain Containing 1A Is a Novel Prognostic Marker for Colorectal Cancer: In vivo Identification from Hypoxic Tumor Cells
Mamoru Uemura, Hirofumi Yamamoto, Ichiro Takemasa, Koshi Mimori, Hideyuki Hemmi, Tsunekazu Mizushima, Masataka Ikeda, Mitsugu Sekimoto, Nariaki Matsura, Yuichiro Dok, and Masaki Mori

4647 A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development
Binsheng Zhao, Geoffrey R. Oxnard, Chaya S. Moskowitz, Mark G. Kris, William Pao, Pingzhen Guo, Valerie M. Rusch, Marc Ladanyi, Naiyer A. Rizvi, and Lawrence H. Schwartz

CORRECTION

4681 Correction: A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies
ABOUT THE COVER

Clinical Use of γH2AX and PAR: Image of an anagen hair bulb plucked from the scalp of a cancer patient 24 hours after drug infusion. γH2AX antibody reveals DNA double-strand breaks (green foci) in cell nuclei (red). Imaged using a Nikon PCM 2000 laser scanning confocal microscope. For details, please see the article by Redon and colleagues on p. 4532 of this issue.